Navigation Links
Uroplasty Reports Third Quarter Fiscal 2009 Results
Date:2/3/2009

4,687 (2,769) Share-based consulting expense 52,567 37,942 Share-based compensation expense 583,013 829,146 Deferred income taxes (11,531) 7,113 Deferred rent (26,250) (26,250) Changes in operating assets and liabilities: Accounts receivable 668,510 (534,542) Inventories (34,427) 64,390 Other current assets and income tax receivable 8,173 191,921 Accounts payable (91,686) 94,198 Accrued liabilities (802,027) 312,158 Accrued pension liability, net (7,585) (247,388) Net cash used in operating activities (668,157) (1,603,028) Cash flows from investing activities: Proceeds from sale of short-term investments 14,157,410 4,200,000 Purchase of short-term investments (7,891,373) (3,648,447) Purchases of property, plant and equipment (181,354) (210,875) Proceeds from sale of equipment - 4,811 Payments for intangible assets (23,282) (92,013) Net cash provided by investing activities 6,061,401 253,476 Cash flows from financing activities: Proceeds from financing obligations - 178,374 Repayment of debt obligations (455,913) (239,872) Net proceeds from issuance of common stock, warrants and option exercise - 5,374,233 Net cash provided by (used in) financing activities (455,913) 5,312,735 Effect of exchange rates
'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
2. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
3. Uroplasty to Host Third Quarter Conference Call on February 11
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
7. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
10. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
11. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 EPFL and the University of  ... of John P. Donoghue . The American neuroscientist ... . The new Wyss Center for ... Geneva , has named as its director ... P. Donoghue , founder of Brown University,s Institute for ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded for ... a second treatment cup to help prevent and smooth skin ... thinner on the edges for a softer contact with the ... surfaces on the face, neck and décolleté. Choose to use ... such as the cheeks and neck, or opt for the ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... , COPENHAGEN, June 4 ... an inhibitor of HIF-1alpha, jointly developed by,Enzon Pharmaceuticals and ... signs of clinical benefit in previously treated cancer patients ... solid,tumors and lymphoma. The study data, which was presented ...
... June 4 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... , , 8th ... Eastern Time at the New York Palace Hotel in New York City. , ... June 18, 2009 at 1:30 p.m. Eastern Time at the Mandarin Oriental Hotel ...
... Austria, June 4 EUCODIS Bioscience, a company,developing ... announced today that it has successfully launched its ... by EUCODIS,Bioscience and can be supplied in a ... antibiotics manufacturers to improve,quality control, to the diagnostics ...
Cached Biology Technology:LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 2LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 3Optimer Pharmaceuticals to Present at June 2009 Investor Conferences 2EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries 2
(Date:7/11/2014)... near the City of Entiat on Tuesday, July 8, ... quickly grew to over 1,000 acres by evening. Three ... under investigation by the Washington Department of Natural Resources. ... resources in developing fire control strategies and tactics. Other ... Department of Natural Resources, (WA DNR), Bureau of Land ...
(Date:7/11/2014)... Institute of Standards and Technology (NIST) need a ... they often prove that necessity is truly the ... for M. Lorna De Leoz and Stephen Stein, ... glycomics. Glycomics is the study of the abundant, ... to proteins and lipids and influence cellular processes, ...
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... Steven Chu announced today the winners of the 2009 E.O. ... supporting the Department of Energy and its missions. The ... citation and $50,000. Winners will be honored at ... made by these researchers to advance the national, economic and ...
... short-term, seasonal exposure to pesticides in rivers and basins ... populations. In addition to the widespread deterioration of salmon ... pesticides may further inhibit the recovery of threatened or ... to restore Pacific salmon habitats in an effort to ...
... , , SUNNYVALE, Calif., Dec. 1 GestureTek ... 3.0 - a turnkey, portable, plug and play interactive ... promotions. GestureTek is the inventor and holder of dozens ... display, presentation and entertainment systems. , Guaranteed for quality, ...
Cached Biology News:Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners 2Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
HIV-1 TAT (vN-21)...
Request Info...
Request Info...
Biology Products: